Physician profile
Rebin Kader
NPI 1174938807
$2,011.30
in general payments reported to CMS, 2019-2025
19 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $770 · 2021: $15.10 · 2022: $261 · 2023: $95.72 · 2024: $78.90 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $682.74 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Phadia US INC. | $295.49 | 2019-2025 | Immunocap |
| Glaxosmithkline, LLC. | $149.07 | 2019-2020 | |
| Genzyme Corporation | $112.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $99.27 | 2023-2025 | |
| Pfizer INC. | $92.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.27 | 2019-2020 | |
| Grifols USA, LLC | $74.82 | 2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $69.85 | 2019-2020 | |
| Electromed, INC. | $56.10 | 2025 | Smartvest |
| Kaleo, INC. | $53.31 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $48.75 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $44.89 | 2023-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $44.29 | 2021-2023 | Takhzyro |
| Optinose US, INC. | $40.37 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $20.98 | 2020 | |
| Horizon Therapeutics Plc | $16.96 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.57 | 2020 | |
| Checkpoint Surgical, INC | $10.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebin Kader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.